Differential possibilities of determination of molecular markers in uterine aspirate in endometrial and non-endometrial cancer of uterine body

Abstract

Objective. To evaluate the diagnostic informativeness of determining the concentration of the MCM5 proliferation marker in the uterine aspirate for the detection of uterine body cancer (UBC) and the differential identifiation of the risk group for patients with suspected non-endometrioid endometrial cancer.Materials and methods. 104 patients diagnosed with UBC and 32 healthy patients of the control group were examined. According to the histological type, 79 (76 %) patients had endometrial cancer, 16 (15 %) had serous and 9 (9 %) clear cell cancer. Endometrial aspiration biopsy was obtained by Pipel biopsy using a two-channel Pipelle catheter. Direct quantitative determination of the concentration of MCM5 in the uterine aspirate cell homogenate was carried out by enzyme-linked immunosorbent assay using specifi MCM5 ELISA test systems.Results. It was found that when the concentration of MCM5 in the uterine aspirate exceeds 11.38 pg/ml, the detection of early-stage UBC is possible with a diagnostic sensitivity of 96.12 % and a specifiity of 78.79 %. When the concentration of MCM5 in the uterine aspirate exceeds 56.9 pg/ml, the relative risk of detecting rare forms of UBC increases (p < 0.0001) by 59.7 times.Conclusions. Determination of the concentration of the protein of the minichromosomal protection family MCM5 in the aspirate of the uterine cavity is informative for the early detection of UBC.